Product Registration Does Not Begin at ANVISA: It Begins with Regulatory Strategy
Many companies believe that the regulatory process starts when documentation is submitted to the Brazilian Health Regulatory Agency (ANVISA). In reality, this is one of the most costly misconceptions for both domestic and international manufacturers seeking access to the Brazilian market.
The truth is that a successful product registration begins long before dossier submission. It depends on a well-structured regulatory strategy capable of anticipating requirements, identifying risks, and creating a safe pathway to commercialization.
The Difference Between Approval and Rework
One of the most significant factors affecting approval timelines is the lack of alignment between a product’s characteristics and its regulatory classification.
Incorrect risk classification, incomplete technical documentation, labeling deficiencies, insufficient clinical evidence, or non-compliance with Brazilian regulations frequently lead to technical deficiencies, delays, and additional costs.
In many cases, investments made in research, manufacturing, and importation are jeopardized by issues that could have been identified during the planning stage.
For this reason, a preliminary regulatory assessment should be viewed as a strategic tool for protecting investments.
The Importance of Regulatory Feasibility Assessment
Before any submission, it is essential to determine whether the product meets Brazilian regulatory requirements and to identify the most appropriate pathway for market authorization.
This assessment typically includes:
• Regulatory classification of the product;
• Identification of applicable regulations and standards;
• Review of available technical documentation;
• Evaluation of certification requirements;
• Good Manufacturing Practices (GMP) considerations;
• Registration or notification strategy;
• Timeline and budget planning.
When conducted by experienced regulatory specialists, this process significantly reduces the likelihood of deficiencies, delays, and unexpected obstacles.
Brazil Requires Planning
The Brazilian market is internationally recognized for its robust regulatory framework governing health-related products.
Medical devices, in vitro diagnostic products, cosmetics, sanitizing products, and other regulated categories are subject to specific requirements that must be considered from the earliest stages of product development.
Ignoring these requirements can transform a promising business opportunity into a lengthy, costly, and unpredictable process.
Regulatory Strategy as a Competitive Advantage
Organizations that incorporate regulatory intelligence into their decision-making processes gain the ability to accelerate approvals, reduce operational costs, and increase the predictability of product launches.
Beyond ensuring compliance, a well-designed regulatory strategy becomes a competitive advantage that facilitates market access and supports long-term business growth.
Product registration does not begin when documentation reaches ANVISA. It begins much earlier—with a solid regulatory strategy developed by experts who understand the complexities and opportunities of the Brazilian regulatory environment.
